Open AccessMAPK/ERK signal pathway alterations in patients with Langerhans Cell Histiocytosis
Author(s) -
Olga Novosad,
Tetiana Skrypets,
Yan Pastushenko,
I. Titorenko,
A. Martynchyk,
O. Skachkova,
M. Inomistova,
Олександр Горбач,
N. Khranovska,
Irina Kryachok
Publication year - 2018
Publication title -
klinická onkologie
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.204
H-Index - 13
eISSN - 1802-5307
pISSN - 0862-495X
DOI - 10.14735/amko2018130
Subject(s) - neuroblastoma ras viral oncogene homolog , kras , langerhans cell histiocytosis , medicine , mapk/erk pathway , mutation , oncology , cancer research , progressive disease , kinase , chemotherapy , cancer , disease , biology , gene , colorectal cancer , biochemistry , microbiology and biotechnology
Clinical outcomes of Langerhans cell histiocytosis (LCH) are highly variable. It has been suggested that mitogen-activated protein kinase (MAPK) /extracellular signal-regulated kinases (ERK) signaling pathway might be activated in LCH patients.